Retinoic acid‐induced autoantigen‐specific type 1 regulatory T cells suppress autoimmunity
Open Access
- 20 March 2019
- journal article
- research article
- Published by Springer Nature in EMBO Reports
- Vol. 20 (5)
Abstract
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.Keywords
Funding Information
- Marie Curie European Fellowship (629498)
- Development Trust of UoA (RG14251)
- Science Foundation Ireland (11/PI/1036)
- Science Foundation Ireland (16/IA/4468)
This publication has 53 references indexed in Scilit:
- The Future of Immunotherapy: A 20-Year PerspectiveFrontiers in Immunology, 2017
- Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesScience Translational Medicine, 2017
- New anti-IL-23 drugs raise hopes for psoriasis plaque clearanceNature Biotechnology, 2016
- Expanding antigen-specific regulatory networks to treat autoimmunityNature, 2016
- Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patientsScience Translational Medicine, 2015
- Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MSNeurology Neuroimmunology & Neuroinflammation, 2015
- Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitisNature Biotechnology, 2012
- Anti-IL-17 mAbs herald new options in psoriasisNature Biotechnology, 2012
- Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune diseaseImmunological Reviews, 2006
- Design of effective immunotherapy for human autoimmunityNature, 2005